Klotho Neurosciences Retains Listing on the NASDAQ

NEW YORK, July 16, 2025 — Klotho Neurosciences, Inc. (referred to as “Klotho” or the “Company”) (NASDAQ: KLTO), a gene and cell therapy firm specializing in the treatment of neurodegenerative and other age-related conditions, today reported receiving official notification from The NASDAQ Stock Market LLC, verifying the Company’s re-establishment of compliance with the NASDAQ Listing Rule 5550(a)(2) for minimum $1.00 bid price, and Listing Rule 5550(b)(1) for the minimum $2.5 million stockholders’ equity.

The Company now fully meets all ongoing NASDAQ listing requirements and will continue to be listed and traded on the NASDAQ Stock Market.

For one year, NASDAQ will maintain oversight of the Company’s adherence to the stockholders’ equity requirement. If the Company were to breach the minimum equity rule within this period, it would face immediate delisting without a typical grace period, though it would retain the option to request a new hearing in such an event.

About Klotho Neurosciences, Inc.
Klotho Neurosciences, Inc. (NASDAQ: KLTO), is a biogenetics firm dedicated to developing cutting-edge, disease-modifying cell and gene therapies. These therapies leverage a protein originating from a patented variant of the human “anti-aging” Klotho gene (s-KL) and innovative delivery methods to revolutionize and enhance the treatment of neurodegenerative and age-related conditions like ALS, Alzheimer’s, and Parkinson’s disease. Its current portfolio comprises proprietary cell and gene therapy initiatives utilizing DNA and RNA as therapeutic agents, alongside genomics-based diagnostic tests. The Company is overseen by a management team and advisors with extensive expertise in biopharmaceutical product development and market introduction.

For additional details, please visit the company’s website at .

Investor Relations and Corporate Communications: – Jeffrey LeBlanc, CFO

Forward-Looking Statements: A Cautionary Note
This press release includes statements that are forward-looking. Such statements are issued pursuant to the “safe harbor” provisions of the 1995 U.S. Private Securities Litigation Reform Act. Typically, these forward-looking statements are recognizable by terms such as “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and comparable phrases. Without limiting the scope of the above, this press release’s forward-looking statements encompass details concerning the Company’s future business activities. Forward-looking statements represent forecasts, projections, and other declarations about future occurrences, grounded in current expectations and assumptions, and consequently, are subject to various risks and uncertainties. Numerous factors could lead actual future events to diverge significantly from the forward-looking statements herein, including but not limited to the Company’s potential inability to execute its business strategies, discover and capitalize on further opportunities, or achieve or surpass its financial forecasts, as well as shifts in the regulatory or competitive landscape where the Company operates. Readers are advised to thoroughly assess the aforementioned factors and other risks and uncertainties detailed in the documents periodically filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”), which could cause actual events and outcomes to differ substantially from those presented in the forward-looking statements. These documents are accessible on the SEC’s website, . All information contained herein is accurate as of the date of this press release, and the Company disclaims any obligation to update any forward-looking statement, unless mandated by applicable law.

SOURCE Klotho Neurosciences, Inc.